Revolution Medicines Azioni (NASDAQ: RVMD)

Ultime notizie per Revolution Medicines (NASDAQ:RVMD) Azioni

Revolution Medicines

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Revolution Medicines, Inc. - Common Stock

Revolution Medicines Inc

Keybanc analyst Jason Celino maintains Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Overweight and raises the price target from $68 to $85.

News

Price Target

Analyst Ratings

PCOR

Keybanc Maintains Overweight on Procore Technologies, Raises Price Target to $85

Stifel analyst Simon Yarmak upgrades Pebblebrook Hotel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) from Hold to Buy and raises the price target from $14.75 to $15.

Upgrades

Stifel Upgrades Pebblebrook Hotel to Buy, Raises Price Target to $15

JP Morgan analyst Alexei Gogolev maintains Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Overweight and raises the price target from $75 to $85.

JP Morgan Maintains Overweight on Procore Technologies, Raises Price Target to $85

Stifel analyst Simon Yarmak downgrades Diamondrock Hospitality (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRH#NYSE">DRH</a>) from Buy to Hold and lowers the price target from $10.75 to $10.25.

Downgrades

Stifel Downgrades Diamondrock Hospitality to Hold, Lowers Price Target to $10.25

DIRECTV announced Friday it would terminate its agreement to acquire EchoStar Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) <a href="https://www.prnewswire.com/news-releases/directv-announces-termination-of-agreement-to-acquire-echostars-video-distribution-business-302313823.html" target="_blank" rel="noreferrer noopener">video distribution business, DISH DBS</a>. 
The decision follows DISH DBS noteholders&#8217; refusal to accept EchoStar&#8217;s proposed Exchange Debt Offer Terms, a critical condition for the deal to proceed. 
EchoStar stock tanked after the update.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42137930/boeing-secures-238-billion-deal-for-advanced-kc-46a-tankers" rel="noreferrer noopener">Boeing Secures $2.38 Billion US Air Force Deal for Advanced KC-46A Tankers</a>
DirecTV CEO Bill Morrow said &#8220;the proposed Exchange Terms were necessary to protect DirecTV&#8217;s balance sheet and our operational flexibility.&#8221;
DirecTV <a target="_blank" href="https://www.benzinga.com/news/24/09/41094002/echostar-stock-dives-on-directv-dish-deal-the-details" rel="noreferrer noopener">agreed to acquire</a> EchoStar&#8217;s video business for $1 and assume Dish DBS&#8217;s net debt. The companies launched an exchange offer for five Dish DBS note series totaling approximately $9.75 billion in face value.
DirecTV plans to continue investing in next-generation streaming technologies and developing new packaging options integrating live TV with direct-to-consumer platforms. The company aims to provide customers with enhanced flexibility and tailored content options that align with evolving viewer preferences.
The termination of the DISH acquisition does not impact TPG&#8217;s plan to purchase the remaining 70% stake in DirecTV from AT&amp;T Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), which remains scheduled to close in the second half of 2025. This strategic move is expected to strengthen DirecTV&#8217;s market positioning further.
EchoStar reported a <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41905346/echostar-q3-earnings-and-sales-falter-but-gains-ground-with-sling-tv-subscribers" rel="noreferrer noopener">third-quarter loss</a> of 52 cents per share, missing analysts&#8217; expected loss of 37 cents. Revenue came in at $3.89 billion, a 5.3%, falling short of the $3.909 billion consensus estimate.
During the quarter, net Pay-TV subscribers declined by 43,000, while Sling TV added 145,000 new users. The company closed the period with 8.03 million Pay-TV subscribers, including 5.89 million for DISH TV and 2.14 million for Sling TV.
Price Action: EchoStar&#8217;s shares are trading lower by 3% to $22.86 at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42137039/disney-takes-on-netflix-with-high-impact-originals-in-asia" target="_blank" rel="noreferrer noopener">Disney Takes on Netflix With High-Impact Originals in Asia</a></li>
</ul>
Image via DirecTV

SATS

EchoStar Shares Sink As DirecTV Terminates Acquisition Agreement

Keybanc analyst Jackson Ader maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Overweight and raises the price target from $345 to $395.

CRWD

Keybanc Maintains Overweight on CrowdStrike Holdings, Raises Price Target to $395

JP Morgan analyst Jeremy Tonet maintains Pembina Pipeline (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PPL#TSX">PPL</a>) with a Neutral and raises the price target from C$62 to C$63.

TSX:PPL

JP Morgan Maintains Neutral on Pembina Pipeline, Raises Price Target to C$63

Stifel analyst Selman Akyol maintains Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) with a Hold and lowers the price target from $70 to $69.

Stifel Maintains Hold on Spire, Lowers Price Target to $69

Stifel analyst Adam Borg maintains Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Buy and raises the price target from $70 to $84.

Stifel Maintains Buy on Procore Technologies, Raises Price Target to $84

Stifel analyst Matthew Sheerin maintains NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) with a Buy and raises the price target from $140 to $145.

NTAP

Stifel Maintains Buy on NetApp, Raises Price Target to $145

Aecom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) shares are trading up Friday, after gaining <a href="https://www.benzinga.com/quote/ACM">around 5% during the week</a>.
The company &#8220;high-graded its portfolio" by increasingly focusing on larger and more complex design projects, where it has the greatest competitive advantage, and is moving further towards program management and advisory, according to Goldman Sachs.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/650419668345120001a2ee65/adam-bubes">Analyst Adam Bubes</a> initiated coverage of Aecom with a Buy rating and price target of $130.
The Aecom Thesis: Engineering News-Record's market data shows that the company has industry-leading design market share in its largest end markets, Bubes said in the initiation note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Bubes noted that Aecom secured the second-highest position in program management, increasing its market share from 6.6% of the top 50 program managers since 2021 to around 11% today.
"We forecast a 6% total company organic growth CAGR through 2027 driven by AECOM's accelerating win rates, double-digit program management and advisory growth, and solid underlying end market trends," the analyst wrote.
Since 2020, Aecom has "divested its self-perform at-risk construction businesses, exited low return countries, and shifted resources to larger and more complex projects," Bubes said. The company's high-graded portfolio is now "driving higher returns at lower risk," he added.
ACM Price Action: Shares of Aecom were up 2.62% at $115.51 at the time of publication on Friday.
Read More: • <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42069454/aecom-reports-q4-results-joins-incyte-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session">Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday&#8217;s Pre-Market Session</a>
Photo: Shutterstock

Analyst Color

Earnings Beats

Long Ideas

Initiation

Movers

Trading Ideas

Aecom Drives 'Higher Returns At Lower Risk,' Says Bullish Analyst

Stifel analyst Rick Wise reiterates Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Buy and raises the price target from $170 to $190.

Reiteration

MASI

Stifel Reiterates Buy on Masimo, Raises Price Target to $190

On November 21, a recent SEC filing unveiled that Resource Group International Ltd, Board Member at IBEX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBEX#NASDAQ">IBEX</a>) made an insider sell.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001720420/000183988224040494//Archives/edgar/data/1720420/000183988224040494/0001839882-24-040494-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, Ltd sold 3,562,341 shares of IBEX. The total transaction value is $70,000,000.
IBEX shares are trading down 0.0% at $21.13 at the time of this writing on Friday morning.
<h3>Discovering IBEX: A Closer Look</h3>
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.
<h3>Unraveling the Financial Story of IBEX</h3>
Revenue Growth: IBEX's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 4.1%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 30.59%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, IBEX exhibits below-average bottom-line performance with a current EPS of 0.45.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.39, IBEX adopts a prudent financial strategy, indicating a balanced approach to debt management.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: IBEX's P/E ratio of 11.24 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.74 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): IBEX's EV/EBITDA ratio, lower than industry averages at 4.64, indicates attractively priced shares.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Exploring Key Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001720420">Check Out The Full List Of IBEX's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

IBEX

Insider Decision: Resource Group International Ltd Offloads $70.00M Worth Of IBEX Stock

Disclosed on November 21, Patrick J McEnany, Director at Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001369568/000116169724000457//Archives/edgar/data/1369568/000116169724000457/0001161697-24-000457-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, McEnany sold 170,845 shares of Catalyst Pharmaceuticals. The total transaction value is $3,627,258.
Monitoring the market, Catalyst Pharmaceuticals's shares up by 1.23% at $21.38 during Friday's morning.
<h3>Discovering Catalyst Pharmaceuticals: A Closer Look</h3>
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
<h3>Breaking Down Catalyst Pharmaceuticals's Financial Performance</h3>
Revenue Growth: Over the 3 months period, Catalyst Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 25.33% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 85.02%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Catalyst Pharmaceuticals's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 0.37.
</li>
</ul>
Debt Management: Catalyst Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Catalyst Pharmaceuticals's P/E ratio of 17.9 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 5.59 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 9.84, Catalyst Pharmaceuticals presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Breaking Down the Significance of Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001369568">Check Out The Full List Of Catalyst Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CPRX

Catalyst Pharmaceuticals Insider Trades Send A Signal

Revealing a significant insider sell on November 21, Michael Gianoni, President and CEO at Blackbaud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLKB#NASDAQ">BLKB</a>), as per the latest SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001280058/000157856324000460//Archives/edgar/data/1280058/000157856324000460/0001578563-24-000460-index.htm">U.S. Securities and Exchange Commission</a> on Thursday outlined that Gianoni executed a sale of 28,571 shares of Blackbaud with a total value of $2,370,648.
Monitoring the market, Blackbaud's shares up by 0.01% at $85.38 during Friday's morning.
<h3>Get to Know Blackbaud Better</h3>
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&amp;A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
<h3>Blackbaud's Economic Impact: An Analysis</h3>
Revenue Growth: Blackbaud displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 3.28%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 55.53%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Blackbaud exhibits below-average bottom-line performance with a current EPS of 0.41.
</li>
</ul>
Debt Management: Blackbaud's debt-to-equity ratio surpasses industry norms, standing at 1.9. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: Blackbaud's current Price to Earnings (P/E) ratio of 84.52 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 3.97 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Blackbaud's EV/EBITDA ratio at 20.47 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001280058">Check Out The Full List Of Blackbaud's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLKB

Michael Gianoni Executes Sell Order: Offloads $2.37M In Blackbaud Stock

It was reported on November 21, that Timothy W Byrne, President &amp; CEO at United States Lime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USLM#NASDAQ">USLM</a>) executed a significant insider sell, according to an SEC filing.
What Happened: Byrne opted to sell 44,215 shares of United States Lime, according to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000082020/000120497524000021//Archives/edgar/data/82020/000120497524000021/0001204975-24-000021-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The transaction's total worth stands at $6,219,751.
Tracking the Friday's morning session, United States Lime shares are trading at $150.9, showing a up of 0.38%.
<h3>Unveiling the Story Behind United States Lime</h3>
United States Lime &amp; Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime, and lime slurry. It supplies its products predominantly to the construction (including highway, road, and building contractors), industrial (including paper and glass manufacturers), environmental (including municipal sanitation and water treatment facilities and flue gas treatment processes), metals (including steel producers), oil and gas services, roof shingle manufacturers and agriculture (including poultry and cattle feed producers) industries. The company operates through its Lime and Limestone Operations segment.
<h3>Understanding the Numbers: United States Lime's Finances</h3>
Revenue Growth: United States Lime's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 19.43%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 48.21%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, United States Lime exhibits below-average bottom-line performance with a current EPS of 1.17.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: United States Lime's current Price to Earnings (P/E) ratio of 43.68 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 14.2 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 29.56, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000082020">Check Out The Full List Of United States Lime's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

USLM

Timothy W Byrne Implements A Sell Strategy: Offloads $6.22M In United States Lime Stock

Making a noteworthy insider sell on November 21, Sarah Nash, Board Member at Blackbaud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLKB#NASDAQ">BLKB</a>), is reported in the latest SEC filing.
What Happened: Nash's decision to sell 1,600 shares of Blackbaud was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001280058/000157856324000462//Archives/edgar/data/1280058/000157856324000462/0001578563-24-000462-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The total value of the sale is $133,542.
The latest update on Friday morning shows Blackbaud shares up by 0.01%, trading at $85.38.
<h3>Discovering Blackbaud: A Closer Look</h3>
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&amp;A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
<h3>Understanding the Numbers: Blackbaud's Finances</h3>
Revenue Growth: Blackbaud displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 3.28%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 55.53%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Blackbaud's EPS is below the industry average. The company faced challenges with a current EPS of 0.41. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.9, caution is advised due to increased financial risk.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 84.52 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 3.97 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a below-average EV/EBITDA ratio of 20.47, Blackbaud presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001280058">Check Out The Full List Of Blackbaud's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Blackbaud Board Member Trades Company's Stock

A substantial insider sell was reported on November 21, by Keith Smith, President and CEO at Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>), based on the recent SEC filing.
What Happened: Smith's recent move involves selling 30,000 shares of Boyd Gaming. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000906553/000106299324019523//Archives/edgar/data/906553/000106299324019523/0001062993-24-019523-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The total value is $2,153,100.
During Friday's morning session, Boyd Gaming shares down by 2.29%, currently priced at $69.88.
<h3>About Boyd Gaming</h3>
Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. Midwest and South hold the key number of entertainment properties, and it generate the majority of sales for the company.
<h3>Boyd Gaming: Delving into Financials</h3>
Revenue Growth: Boyd Gaming displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 6.43%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 51.95%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Boyd Gaming's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 1.43.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 2.35, Boyd Gaming adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 13.6 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 1.78 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 9.05, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Exploring Key Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000906553">Check Out The Full List Of Boyd Gaming's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sell Alert: Keith Smith Cashes Out $2.15M In Boyd Gaming Stock

JAYNIE STUDENMUND, Board Member at ExlService Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXLS#NASDAQ">EXLS</a>), executed a substantial insider sell on November 21, according to an SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001297989/000162828024048873//Archives/edgar/data/1297989/000162828024048873/0001628280-24-048873-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that STUDENMUND sold 3,645 shares of ExlService Holdings. The total transaction amounted to $160,562. 
Tracking the Friday's morning session, ExlService Holdings shares are trading at $46.0, showing a up of 0.74%.
<h3>Unveiling the Story Behind ExlService Holdings</h3>
ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage company's deep expertise in analytics, AI, ML and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging, Analytics. The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.
<h3>A Deep Dive into ExlService Holdings's Financials</h3>
Revenue Growth: ExlService Holdings's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 14.87%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company shows a low gross margin of 37.76%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, ExlService Holdings exhibits below-average bottom-line performance with a current EPS of 0.33.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.47, ExlService Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 40.05, ExlService Holdings's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 4.26 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 22.1 is above the industry average, suggesting that the market values the company more highly for each unit of EBITDA. This could be attributed to factors such as strong growth prospects or superior operational efficiency.
</li>
</ul>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Cracking Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001297989">Check Out The Full List Of ExlService Holdings's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXLS

ExlService Holdings Board Member Trades $160K In Company Stock

On November 21, a substantial insider purchase was made by CARL ICAHN, 10% Owner at CVR Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAN#NYSE">UAN</a>), as per the latest SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001425292/000106299324019527//Archives/edgar/data/1425292/000106299324019527/0001062993-24-019527-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that ICAHN purchased 19,174 shares of CVR Partners. The total transaction amounted to $1,374,040. 
In the Friday's morning session, CVR Partners's shares are currently trading at $72.0, experiencing a up of 0.53%.
<h3>Get to Know CVR Partners Better</h3>
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
<h3>A Deep Dive into CVR Partners's Financials</h3>
Negative Revenue Trend: Examining CVR Partners's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -4.13% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: With a low gross margin of 14.73%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): CVR Partners's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 0.36.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 1.92, CVR Partners faces challenges in effectively managing its debt levels, indicating potential financial strain.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 14.41 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 1.44 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 7.18 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001425292">Check Out The Full List Of CVR Partners's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Noteworthy Insider Activity: CARL ICAHN Invests $1.37M In CVR Partners Stock

TD Cowen analyst Marc Frahm has maintained their bullish stance on RVMD stock, giving a Buy rating on November 4. Marc Frahm has given his Buy rati...

Revolution Medicines: Strong Buy Rating Backed by Financial Stability and Promising Cancer Treatment Advances

Revolution Medicines, Inc. ( ($RVMD) ) has released its Q3 earnings. Here is a breakdown of the information Revolution Medicines, Inc. presented to...

Revolution Medicines Reports Q3 2024 Results and Progress

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CVS Health (CVS – Research Report), Revolution Medic...

Analysts' Top Healthcare Picks: CVS Health (CVS), Revolution Medicines (RVMD)

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Revolution Medicines (RVMD – Research Report). The associated price tar...

Revolution Medicines: Strong Financial Position and Upcoming Clinical Milestones Justify Buy Rating with Increased Price Target

In a report released today, Ami Fadia from Needham maintained a Buy rating on Revolution Medicines (RVMD – Research Report), with a price target of...

Optimistic Growth Prospects for Revolution Medicines with Promising Data Updates and Increased Price Target

Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Revolution Medicines (RVMD – Research Report) on November 8 and set a price tar...

Stifel Nicolaus Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

In a report released on November 7, Jonathan Chang from Leerink Partners reiterated a Buy rating on Revolution Medicines (RVMD – Research Report), ...

Promising Outlook for Revolution Medicines: Buy Rating Backed by Strong RAS ON Inhibitor Progress and Financial Stability

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Revolution Medicines (RVMD – Research Report)...

Revolution Medicines (RVMD) Receives a Buy from Bank of America Securities

Jefferies initiated coverage of Erasca (ERAS) with a Buy rating and $6 price target. The firm sees appeal in the company's valuation, citing the co...

Erasca initiated with a Buy at Jefferies

JPMorgan's 'Analyst Focus List' – growth, income, value, short ideas

AGCO

ALRM

AMZN

ARMK

ASND

AVGO

BRBR

CVNA

CYBR

DAWN

DELL

DKNG

ERAS

EWTX

GWRE

ISRG

KLAC

KVUE

LEGN

MNDY

MSFT

NTRA

PODD

ROIV

RVMD

SCHW

SIRI

SNDX

SPGI

SWTX

TFII

TMUS

TRGP

TVTX

ULTA

VICI

XENE

Health Care

Press Releases

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

Earnings

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Comments

Revolution Medicines

Notizie

Ultime notizie per Revolution Medicines (NASDAQ:RVMD) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO